Literature DB >> 1392325

The antitumor activity and immunosuppressive effects of 5-fluorouracil suppositories in rectal cancer patients.

W Adachi1, A Sugenoya, N Horigome, C Takahashi, F Iida, J Nakayama.   

Abstract

The antitumor activity and immunological effects of the local administration of 5FU were investigated by determining the tissue concentration of 5FU, histological appearance of the primary tumor, and lymphocyte subsets of the regional lymph nodes in 23 rectal cancer patients. Twelve patients were treated with 5FU suppositories preoperatively, being the 5FU group, while 11 patients were given no preoperative treatment, being the control group. The 5FU concentrations in the primary tumors were higher than those in the regional lymph nodes and appeared to remain high for an extended period. No histological changes peculiar to the 5FU group were observed in the primary tumors. An analysis of the lymphocyte subsets in the pararectal nodes revealed that Leu2a+15- cells, or cytotoxic T lymphocytes, were significantly decreased in numbers in the 5FU group compared to the control group. These results suggest that the local use of 5FU may not only exert an antitumor effect against rectal cancer, but can also cause the suppression of antitumor immunity in the regional lymph nodes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1392325     DOI: 10.1007/bf00308826

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  15 in total

Review 1.  Immunologic aspects of cancer chemotherapy.

Authors:  C M Haskell
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

2.  Differential chemotherapeutic susceptibility of human T-lymphocytes and B-lymphocytes in culture.

Authors:  T Ohnuma; H Arkin; J Minowada; J F Holland
Journal:  J Natl Cancer Inst       Date:  1978-04       Impact factor: 13.506

3.  Characterization of human lymphocyte subpopulations: alloreactive cytotoxic T-lymphocyte precursor and effector cells are phenotypically distinct from Leu 2+ suppressor cells.

Authors:  L T Clement; M K Dagg; A Landay
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

4.  Analysis of tissue lymphocytes by double fluorescent staining--gastric cancer tissue and regional lymph nodes.

Authors:  I Takeda; T Horimi; T Okabayashi; S Nagae; S Chono; N Tokuda; K Orita
Journal:  Jpn J Surg       Date:  1987-05

5.  A unique human B lymphocyte antigen defined by a monoclonal antibody.

Authors:  T C Meeker; R A Miller; M P Link; J Bindl; R Warnke; R Levy
Journal:  Hybridoma       Date:  1984

6.  Clinical studies of intrarectal administration of 5-FU emulsion as an adjunct to surgical treatment of rectal cancer.

Authors:  B Nishioka; S Watanabe; Y Fijita; O Kojima; K Morisawa; E Yamane; M Umehara; S Majima
Journal:  Jpn J Surg       Date:  1980-06

7.  Preoperative use of 5-fluorouracil suppository for carcinoma of the rectum.

Authors:  T Takahashi; K Kohno; T Yamaguchi; T Narisawa
Journal:  Am J Surg       Date:  1982-02       Impact factor: 2.565

8.  The action of 7-N-(p-hydroxyphenyl)mitomycin C [M-83] in suppressing murine immune response.

Authors:  M Okabe; R Imai; M Morimoto
Journal:  J Antibiot (Tokyo)       Date:  1982-08       Impact factor: 2.649

9.  Dissection of immunoregulatory subpopulations of T lymphocytes within the helper and suppressor sublineages in man.

Authors:  P A Gatenby; G S Kansas; C Y Xian; R L Evans; E G Engleman
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

10.  Immune competent cells of regional lymph nodes in colorectal cancer patients: I. Flow cytometric analysis of lymphocyte subpopulation.

Authors:  W Adachi; A Sugenoya; F Iida
Journal:  J Surg Oncol       Date:  1991-02       Impact factor: 3.454

View more
  1 in total

1.  Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model.

Authors:  Tove Selvin; Erik Fasterius; Malin Jarvius; Mårten Fryknäs; Rolf Larsson; Claes R Andersson
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.